Influence of Genetic Polymorphisms on the Effect of High-and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention The GIFT (Genotype Information and Functional Testing) Study

被引：107

作者：

Price, Matthew J. ^{[1
,2
]}

Murray, Sarah S. ^{[2
]}

Angiolillo, Dominick J. ^{[3
]}

Lillie, Elizabeth ^{[2
]}

Smith, Erin N. ^{[4
,5
]}

Tisch, Rebecca L. ^{[2
]}

Schork, Nicholas J. ^{[2
]}

Teirstein, Paul S. ^{[1
]}

Topol, Eric J. ^{[1
,2
]}

机构：

[1] Scripps Clin, Div Cardiovasc Dis, La Jolla, CA 92037 USA

[2] Scripps Translat Sci Inst, La Jolla, CA USA

[3] Univ Florida, Div Cardiol, Jacksonville, FL USA

[4] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA

[5] Univ Calif San Diego, Sch Med, Radys Childrens Hosp, La Jolla, CA 92093 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2012年 / 59卷 / 22期

关键词：

clopidogrel; CYP2C19; genotype; platelet function testing; thienipyridine; OF-FUNCTION POLYMORPHISM; PLATELET REACTIVITY; CYP2C19; GENOTYPE; STENT THROMBOSIS; TREATED PATIENTS; CARDIOVASCULAR OUTCOMES; RESPONSE VARIABILITY; CLINICAL-OUTCOMES; MAJOR DETERMINANT; IMPACT;

D O I：

10.1016/j.jacc.2011.11.068

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives This study sought to evaluate the influence of single nucleotide polymorphisms (SNPs) on the pharmacodynamic effect of high-or standard-dose clopidogrel after percutaneous coronary intervention (PCI). Background There is a lack of prospective, multicenter data regarding the effect of different genetic variants on clopidogrel pharmacodynamics over time in patients undergoing PCI. Methods The GRAVITAS (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety) trial screened patients with platelet function testing after PCI and randomly assigned those with high on-treatment reactivity (OTR) to either high-or standard-dose clopidogrel; a cohort of patients without high OTR were also followed. DNA samples obtained from 1,028 patients were genotyped for 41 SNPs in 17 genes related to platelet reactivity. After adjusting for clinical characteristics, the associations between the SNPs and OTR using linear regression were evaluated. Results CYP2C19(star)2 was significantly associated with OTR at 12 to 24 h (R-2 = 0.07, p = 2.2 x 10(-15)), 30 days (R-2 = 0.10, p = 1.3 x 10(-7)), and 6 months after PCI (R-2 = 0.07, p = 1.9 x 10(-11)), whereas PON1, ABCB1 3435 C -> T, and other candidate SNPs were not. Carriers of 1 and 2 reduced-function CYP2C19 alleles were significantly more likely to display persistently high OTR at 30 days and 6 months, irrespective of treatment assignment. The portion of the risk of persistently high OTR at 30 days attributable to reduced-function CYP2C19 allele carriage was 5.2% in the patients randomly assigned to high-dose clopidogrel. Conclusions CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynamic effects of clopidogrel, both early and late after PCI. In patients with high OTR identified by platelet function testing, the CYP2C19 genotype provides limited incremental information regarding the risk of persistently high reactivity with clopidogrel 150-mg maintenance dosing. (Genotype Information and Functional Testing Study [GIFT]; NCT00992420) (J Am Coll Cardiol 2012; 59: 1928-37) (C) 2012 by the American College of Cardiology Foundation

引用

页码：1928 / 1937

页数：10

共 41 条

[21] Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis [J].

Mega, Jessica L. ;

Simon, Tabassome ;

Collet, Jean-Philippe ;

Anderson, Jeffrey L. ;

Antman, Elliott M. ;

Bliden, Kevin ;

Cannon, Christopher P. ;

Danchin, Nicolas ;

Giusti, Betti ;

Gurbel, Paul ;

Horne, Benjamin D. ;

Hulot, Jean-Sebastian ;

Kastrati, Adnan ;

Montalescot, Gilles ;

Neumann, Franz-Josef ;

Shen, Lei ;

Sibbing, Dirk ;

Steg, P. Gabriel ;

Trenk, Dietmar ;

Wiviott, Stephen D. ;

Sabatine, Marc S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16) :1821-1830

[22] Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment [J].

Pare, Guillaume ;

Mehta, Shamir R. ;

Yusuf, Salim ;

Anand, Sonia S. ;

Connolly, Stuart J. ;

Hirsh, Jack ;

Simonsen, Katy ;

Bhatt, Deepak L. ;

Fox, Keith A. A. ;

Eikelboom, John W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1704-1714

[23] Onset and offset of platelet inhibition after high-dose Clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers [J].

Price, Matthew J. ;

Coleman, Jacqueline L. ;

Steinhubl, Steven R. ;

Wong, Garrett B. ;

Cannon, Christopher P. ;

Teirstein, Paul S. .

AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (05) :681-684

[24] Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial [J].

Price, Matthew J. ;

Angiolillo, Dominick J. ;

Teirstein, Paul S. ;

Lillie, Elizabeth ;

Manoukian, Steven V. ;

Berger, Peter B. ;

Tanguay, Jean-Francois ;

Cannon, Christopher P. ;

Topol, Eric J. .

CIRCULATION, 2011, 124 (10) :1132-1137

[25] Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention The GRAVITAS Randomized Trial [J].

Price, Matthew J. ;

Berger, Peter B. ;

Teirstein, Paul S. ;

Tanguay, Jean-Francois ;

Angiolillo, Dominick J. ;

Spriggs, Douglas ;

Puri, Sanjeev ;

Robbins, Mark ;

Garratt, Kirk N. ;

Bertrand, Olivier F. ;

Stillablower, Michael E. ;

Aragon, Joseph R. ;

Kandzari, David E. ;

Stinis, Curtiss T. ;

Lee, Michael S. ;

Manoukian, Steven V. ;

Cannon, Christopher P. ;

Schork, Nicholas J. ;

Topol, Eric J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (11) :1097-1105

[26] Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial [J].

Price, Matthew J. ;

Berger, Peter B. ;

Angiolillo, Dominick J. ;

Teirstein, Paul S. ;

Tanguay, Jean-Francois ;

Kandzari, David E. ;

Cannon, Christopher P. ;

Topol, Eric J. .

AMERICAN HEART JOURNAL, 2009, 157 (05) :818-824

[27] Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics -: The PCI-CLARITY study [J].

Sabatine, MS ;

Cannon, CP ;

Gibson, CM ;

López-Sendón, JL ;

Montalescot, G ;

Theroux, P ;

Lewis, BS ;

Murphy, SA ;

McCabe, CH ;

Braunwald, E .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (10) :1224-1232

[28] Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy [J].

Shuldiner, Alan R. ;

O'Connell, Jeffrey R. ;

Bliden, Kevin P. ;

Gandhi, Amish ;

Ryan, Kathleen ;

Horenstein, Richard B. ;

Damcott, Coleen M. ;

Pakyz, Ruth ;

Tantry, Udaya S. ;

Gibson, Quince ;

Pollin, Toni I. ;

Post, Wendy ;

Parsa, Afshin ;

Mitchell, Braxton D. ;

Faraday, Nauder ;

Herzog, William ;

Gurbel, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (08) :849-858

[29] No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting [J].

Sibbing, Dirk ;

Koch, Werner ;

Massberg, Steffen ;

Byrne, Robert A. ;

Mehilli, Julinda ;

Schulz, Stefanie ;

Mayer, Katharina ;

Bernlochner, Isabell ;

Schoemig, Albert ;

Kastrati, Adnan .

EUROPEAN HEART JOURNAL, 2011, 32 (13) :1605-1613

[30] Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement [J].

Sibbing, Dirk ;

Koch, Werner ;

Gebhard, Daniela ;

Schuster, Tibor ;

Braun, Siegmund ;

Stegherr, Julia ;

Morath, Tanja ;

Schoemig, Albert ;

von Beckerath, Nicolas ;

Kastrati, Adnan .

CIRCULATION, 2010, 121 (04) :512-518

← 1 2 3 4 5 →